Augmentin Chewable FDA

Consumer Information (PDR):

Consumer Information (MedFacts):

Consumer Information (Cerner Multum):

Advanced Consumer Information (Micromedex):

Professional Monographs (FDA):

Pharmacy FAQ

What is online pharmacy?

Since about the year 2000, hundreds of pharmacies have begun operating over the internet.
Many such pharmacies are, in some ways, similar to community pharmacies; the primary difference is the method by which the medications are reques... more >>

What does the term "generic" mean? Do generic medications produce the same effect as the brand name medicines do?

The difference between a brand name medicine and a generic one is in the name, shape and in the price. A generic drug is usually called by the name of... more >>

Why are generic medicines so cheap?

Generics are much cheaper than brand-name drugs because generic companies do not have overhead cost such as research and marketing. Most generic drugs are manufactured off-shore and sold online. Since manufacturers do not spend ... more >>

Are generic drugs as reliable as brand name pills?

Generic drugs are tested under the same standards as brand-name drugs. Each generic drug is laboratory tested so that the same amount is absorbed into the body as with brand-name drugs.
The FDA (U.S Food and D... more >>

Generic pills do not look like the brand name medication. The pills have a different name printed on them. Why?

As we have already mentioned that no manufacturer can take out a patent for a chemical agent. Thus generics can have the exactly same active ingredient... more >>

Are generic drugs patented?

No, but having a patent does not make it any more reliable.

... more >>
Buy Augmentin Online
Best Prices on High-Quality Generic Drugs!
No Prescription Needed - Fast Worldwide Delivery!

www.ameritrustdrugs.com
Generic Augmentin (Amoxicillin And Clavulanate)
Generic Augmentin and Other Antibiotics Medications. Order Augmentin Online Now! Fast Worldwide Delivery!
www.rx-genericpharmacy.com

Augmentin Chewable FDA

Augmentin Chewable


Generic Name: amoxicillin and clavulanate potassium
Dosage Form: Chewable Tablets and Powder for Oral Suspension

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN (amoxicillin/clavulanate potassium) and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Augmentin Chewable Description

AUGMENTIN is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The amoxicillin molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.46. Chemically, amoxicillin is (2S,5R,6R) - 6 - [(R) - ( - ) - 2 - Amino - 2 - (p - hydroxyphenyl)acetamido] - 3,3 - dimethyl - 7 - oxo - 4 - thia - 1 - azabicyclo[3.2.0]heptane - 2 - carboxylic acid trihydrate and may be represented structurally as:

augmentin

Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus . It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C8H8KNO5, and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)-(2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as:

augmentin

Inactive Ingredients

Powder for Oral Suspension—Colloidal silicon dioxide, flavorings (see HOW SUPPLIED), xanthan gum, and 1 or more of the following: Aspartame•, hypromellose, mannitol, silica gel, silicon dioxide, and sodium saccharin. Chewable Tablets—Colloidal silicon dioxide, flavorings (see HOW SUPPLIED), magnesium stearate, mannitol, and 1 or more of the following: Aspartame•, D&C Yellow No. 10, FD&C Red No. 40, glycine, sodium saccharin and succinic acid.

•See PRECAUTIONS—Information for the Patient.

Each 125-mg chewable tablet and each 5 mL of reconstituted 125 mg/5 mL oral suspension of AUGMENTIN contains 0.16 mEq potassium. Each 250-mg chewable tablet and each 5 mL of reconstituted 250 mg/5 mL oral suspension of AUGMENTIN contains 0.32 mEq potassium. Each 200-mg chewable tablet and each 5 mL of reconstituted 200 mg/5 mL oral suspension of AUGMENTIN contains 0.14 mEq potassium. Each 400-mg chewable tablet and each 5 mL of reconstituted 400 mg/5 mL oral suspension of AUGMENTIN contains 0.29 mEq of potassium.

Augmentin Chewable - Clinical Pharmacology

Amoxicillin and clavulanate potassium are well absorbed from the gastrointestinal tract after oral administration of AUGMENTIN. Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While AUGMENTIN can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In 1 study, the relative bioavailability of clavulanate was reduced when AUGMENTIN was dosed at 30 and 150 minutes after the start of a high-fat breakfast. The safety and efficacy of AUGMENTIN have been established in clinical trials where AUGMENTIN was taken without regard to meals.

Oral administration of single doses of 400-mg chewable tablets of AUGMENTIN and 400 mg/5 mL suspension to 28 adult volunteers yielded comparable pharmacokinetic data:

Dose

AUC0-∞ (mcg.hr/mL)

Cmax (mcg/mL)

(amoxicillin/clavulanate potassium)

amoxicillin

(±S.D.)

clavulanate potassium

(±S.D.)

amoxicillin (±S.D.)

clavulanate potassium (±S.D.)

400/57 mg

(5 mL of suspension)

17.29 ± 2.28

2.34 ± 0.94

6.94 ± 1.24

1.10 ± 0.42

400/57 mg

(1 chewable tablet)

17.24 ± 2.64

2.17 ± 0.73

6.67 ± 1.37

1.03 ± 0.33

Administered at the start of a light meal.

Mean values of 28 normal volunteers. Peak concentrations occurred approximately 1 hour after the dose.

Oral administration of 5 mL of 250 mg/5 mL suspension of AUGMENTIN or the equivalent dose of 10 mL of 125 mg/5 mL suspension of AUGMENTIN provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg.hr/mL for amoxicillin and 2.9 mcg.hr/mL for clavulanic acid when 5 mL of 250 mg/5 mL suspension of AUGMENTIN or equivalent dose of 10 mL of 125 mg/5 mL suspension of AUGMENTIN was administered to adult volunteers. One 250-mg chewable tablet of AUGMENTIN or two 125-mg chewable tablets of AUGMENTIN are equivalent to 5 mL of 250 mg/5 mL suspension of AUGMENTIN and provide similar serum levels of amoxicillin and clavulanic acid.

Amoxicillin serum concentrations achieved with AUGMENTIN are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. The half-life of amoxicillin after the oral administration of AUGMENTIN is 1.3 hours and that of clavulanic acid is 1.0 hour. Time above the minimum inhibitory concentration of 1.0 mcg/mL for amoxicillin has been shown to be similar after corresponding q12h and q8h dosing regimens of AUGMENTIN in adults and children.

Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of 10 mL of 250 mg/5 mL suspension of AUGMENTIN.

Concurrent administration of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid.

Neither component in AUGMENTIN is highly protein-bound; clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound.

Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. The results of experiments involving the administration of clavulanic acid to animals suggest that this compound, like amoxicillin, is well distributed in body tissues.

Two hours after oral administration of a single 35 mg/kg dose of suspension of AUGMENTIN to fasting children, average concentrations of 3.0 mcg/mL of amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in middle ear effusions.

Microbiology

Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Amoxicillin is, however, susceptible to degradation by β-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a β-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range ofβ-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance.

The formulation of amoxicillin and clavulanic acid in AUGMENTIN protects amoxicillin from degradation by β-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other β-lactam antibiotics. Thus, AUGMENTIN possesses the distinctive properties of a broad-spectrum antibiotic and a β-lactamase inhibitor.

Amoxicillin/clavulanic acid has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in INDICATIONS AND USAGE.

Gram-Positive Aerobes

Staphylococcus aureus (β-lactamase and non−β-lactamase−producing)§

§ Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.

Gram-Negative Aerobes

Enterobacter species (Although most strains of Enterobacter species are resistant in vitro, clinical efficacy has been demonstrated with AUGMENTIN in urinary tract infections caused by these organisms.)

Escherichia coli (β-lactamase and non−β-lactamase−producing)

Haemophilus influenzae (β-lactamase and non−β-lactamase−producing)

Klebsiella species (All known strains are β-lactamase−producing.)

Moraxella catarrhalis (β-lactamase and non−β-lactamase−producing)

The following in vitro data are available, but their clinical significance is unknown.

Amoxicillin/clavulanic acid exhibits in vitro minimal inhibitory concentrations (MICs) of 2 mcg/mL or less against most (≥90%) strains of Streptococcus pneumoniae; MICs of 0.06 mcg/mL or less against most (≥90%) strains of Neisseria gonorrhoeae; MICs of 4 mcg/mL or less against most (≥90%) strains of staphylococci and anaerobic bacteria; MICs of 8 mcg/mL or less against most (≥90%) strains of other listed organisms. However, with the exception of organisms shown to respond to amoxicillin alone, the safety and effectiveness of amoxicillin/clavulanic acid in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

Because amoxicillin has greater in vitro activity against S.pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin.

Gram-Pos

itive Aerobes

Enterococcus faecalis

Staphylococcus epidermidis (β-lactamase and non−β-lactamase−producing)

Staphylococcus saprophyticus (β-lactamase and non−β-lactamase−producing)

Streptococcus pneumoniae¶**

Streptococcus pyogenes¶**

viridans group Streptococcus¶**

Gram-Negative Aerobes

Eikenella corrodens (β-lactamase and non−β-lactamase−producing)

Neisseria gonorrhoeae(β-lactamase and non−β-lactamase−producing)

Proteus mirabilis (β-lactamase and non−β-lactamase−producing)

Anaerobic Bacteria

Bacteroides species, including Bacteroides fragilis (β-lactamase and non−β-lactamase−producing)

Fusobacterium species (β-lactamase and non−β-lactamase−producing)

Peptostreptococcus species**

Adequate and well-controlled clinical trials have established the effectiveness of amoxicillin alone in treating certain clinical infections due to these organisms.

** These are non−β-lactamase−producing organisms, and therefore, are susceptible to amoxicillin alone.

Susceptibility Testing

Dilution Techniques

Quantitative methods are used to determine antimicrobial MICs. These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of amoxicillin/clavulanate potassium powder.

The recommended dilution pattern utilizes a constant amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with varying amounts of amoxicillin. MICs are expressed in terms of the amoxicillin concentration in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid. The MIC values should be interpreted according to the following criteria:

RECOMMENDED RANGES FOR AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBILITY TESTING

For Gram-Negative Enteric Aerobes:

MIC (mcg/mL)

Interpretation

≤8/4

Susceptible (S)

16/8

Intermediate (I)

≥32/16

Resistant (R)

For Staphylococcus†† and Haemophilus species:

MIC (mcg/mL)

Interpretation

≤4/2

Susceptible (S)

≥8/4

Resistant (R)

†† Staphylococci which are susceptible to amoxicillin/clavulanic acid but resistant to methicillin/oxacillin must be considered as resistant.

ForS. pneumoniae from non-meningitis sources: Isolates should be tested using amoxicillin/clavulanic acid and the following criteria should be used:

MIC (mcg/mL)

Interpretation

≤2/1

Susceptible (S)

4/2

Intermediate (I)

≥8/4

Resistant (R)

Note: These interpretive criteria are based on the recommended doses for respiratory tract infections.

A report of“Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard amoxicillin/clavulanate potassium powder should provide the following MIC values:

Microorganism

MIC Range (mcg/mL)‡‡

E. coli ATCC 25922

2 to 8

E. coli ATCC 35218

4 to 16

E. faecalis ATCC 29212

0.25 to 1.0

H. influenzae ATCC 49247

2 to 16

S. aureus ATCC 29213

0.12 to 0.5

S. pneumoniae ATCC 49619

0.03 to 0.12

‡‡ Expressed as concentration of amoxicillin in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid.

Diffusion Techniques

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure2 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg of amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) to test the susceptibility of microorganisms to amoxicillin/clavulanic acid.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) disk should be interpreted according to the following criteria:

RECOMMENDED RANGES FOR AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBILITY TESTING

ForStaphylococcus§§ species and H. influenzaea:

Zone Diameter (mm)

Interpretation

≥20

Susceptible (S)

≤19

Resistant (R)

For Other Organisms Except S.pneumoniaeb and N.gonorrhoeaec:

Zone Diameter (mm)

Interpretation

≥18

Susceptible (S)

14 to 17

Intermediate (I)

≤13

Resistant (R)

§§Staphylococci which are resistant to methicillin/oxacillin must be considered as resistant to amoxicillin/clavulanic acid.

a A broth microdilution method should be used for testing H. influenzae. Beta-lactamase−negative, ampicillin-resistant strains must be considered resistant to amoxicillin/clavulanic acid.

b Susceptibility of S. pneumoniae should be determined using a 1-mcg oxacillin disk. Isolates with oxacillin zone sizes of ≥20 mm are susceptible to amoxicillin/clavulanic acid. An amoxicillin/clavulanic acid MIC should be determined on isolates of S. pneumoniae with oxacillin zone sizes of ≤19 mm.

c A broth microdilution method should be used for testing N. gonorrhoeae and interpreted according to penicillin breakpoints.

Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for amoxicillin/clavulanic acid.

As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30-mcg amoxicillin/clavulanate potassium (20mcg amoxicillin plus 10mcg clavulanate potassium) disk should provide the following zone diameters in these laboratory quality control strains:

Microorganism

Zone Diameter (mm)

E. coli ATCC 25922

19 to 25 mm

E. coli ATCC 35218

18 to 22 mm

S. aureus ATCC 25923

28 to 36 mm

Indications and Usage for Augmentin Chewable

AUGMENTIN is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:

Lower Respiratory Tract Infections − caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis.

Otitis Media− caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis.

Sinusitis− caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis.

Skin and Skin Structure Infections− caused by β-lactamase−producing strains of S. aureus, E. coli, and Klebsiella spp.

Urinary Tract Infections− caused by β-lactamase−producing strains of E. coli, Klebsiella spp. and Enterobacter spp.

While AUGMENTIN is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with AUGMENTIN due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase−producing organisms susceptible to AUGMENTIN should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and AUGMENTIN. (See Microbiology.)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Bacteriological studies, to determine the causative organisms and their susceptibility to AUGMENTIN, should be performed together with any indicated surgical procedures.

Contraindications

AUGMENTIN is contraindicated in patients with a history of allergic reactions to any penicillin. It is also contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with AUGMENTIN.

Warnings

SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH AUGMENTIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, AUGMENTIN SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including AUGMENTIN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

AUGMENTIN should be used with caution in patients with evidence of hepatic dysfunction. Hepatic toxicity associated with the use of AUGMENTIN is usually reversible. On rare occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications. (See CONTRAINDICATIONS and ADVERSE REACTIONS—Liver.)

Precautions

General

While AUGMENTIN possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy.

A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash. Thus, ampicillin-class antibiotics should not be administered to patients with mononucleosis.

The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving Pseudomonas or Candida), the drug should be discontinued and/or appropriate therapy instituted.

Prescribing AUGMENTIN in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for the Patient

AUGMENTIN may be taken every 8 hours or every 12 hours, depending on the strength of the product prescribed. Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset. Many antibiotics can cause diarrhea. If diarrhea is severe or lasts more than 2 or 3 days, call your doctor.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Keep suspension refrigerated. Shake well before using. When dosing a child with the suspension (liquid) of AUGMENTIN, use a dosing spoon or medicine dropper. Be sure to rinse the spoon or dropper after each use. Bottles of suspension of AUGMENTIN may contain more liquid than required. Follow your doctor’s instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine.

Patients should be counseled that antibacterial drugs including AUGMENTIN, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When AUGMENTIN is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by AUGMENTIN or other antibacterial drugs in the future.

Phenylketonurics

Each 200-mg chewable tablet of AUGMENTIN contains 2.1 mg phenylalanine; each 400-mg chewable tablet contains 4.2 mg phenylalanine; each 5 mL of either the 200 mg/5 mL or 400 mg/5 mL oral suspension contains 7 mg phenylalanine. The other products of AUGMENTIN do not contain phenylalanine and can be used by phenylketonurics. Contact your physician or pharmacist.

Drug Interactions

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with AUGMENTIN may result in increased and prolonged blood levels of amoxicillin. Coadministration of probenecid cannot be recommended.

The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with AUGMENTIN and allopurinol administered concurrently.

In common with other broad-spectrum antibiotics, AUGMENTIN may reduce the efficacy of oral contraceptives.

Drug/Laboratory Test Interactions

Oral administration of AUGMENTIN will result in high urine concentrations of amoxicillin. High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST®, Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin and therefore AUGMENTIN, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX®) be used.

Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted. This effect may also occur with amoxicillin and therefore AUGMENTIN.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Mutagenesis

The mutagenic potential of AUGMENTIN was investigated in vitro with an Ames test, a human lymphocyte cytogenetic assay, a yeast test and a mouse lymphoma forward mutation assay, and in vivo with mouse micronucleus tests and a dominant lethal test. All were negative apart from the in vitro mouse lymphoma assay where weak activity was found at very high, cytotoxic concentrations.

Impairment of Fertility

AUGMENTIN at oral doses of up to 1,200 mg/kg/day (5.7 times the maximum human dose, 1,480 mg/m2/day, based on body surface area) was found to have no effect on fertility and reproductive performance in rats, dosed with a 2:1 ratio formulation of amoxicillin:clavulanate.

Teratogenic effects

Pregnancy (Category B). Reproduction studies performed in pregnant rats and mice given AUGMENTIN at oral dosages up to 1,200 mg/kg/day, equivalent to 7,200 and 4,080 mg/m2/day, respectively (4.9 and 2.8 times the maximum human oral dose based on body surface area), revealed no evidence of harm to the fetus due to AUGMENTIN. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery

Oral ampicillin-class antibiotics are generally poorly absorbed during labor. Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of AUGMENTIN in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary. In a single study in women with premature rupture of fetal membranes, it was reported that prophylactic treatment with AUGMENTIN may be associated with an increased risk of necrotizing enterocolitis in neonates.

Nursing Mothers

Ampicillin-class antibiotics are excreted in the milk; therefore, caution should be exercised when AUGMENTIN is administered to a nursing woman.

Pediatric Use

Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of AUGMENTIN should be modified in pediatric patients younger than 12 weeks (3 months). (See DOSAGE AND ADMINISTRATION—Pediatric.)

Adverse Reactions

AUGMENTIN is generally well tolerated. The majority of side effects observed in clinical trials were of a mild and transient nature and less than 3% of patients discontinued therapy because of drug-related side effects. From the original premarketing studies, where both pediatric and adult patients were enrolled, the most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). The overall incidence of side effects, and in particular diarrhea, increased with the higher recommended dose. Other less frequently reported reactions include: Abdominal discomfort, flatulence, and headache.

In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided q12h) of AUGMENTIN for 10 days versus 40/10 mg/kg/day (divided q8h) of AUGMENTIN for 10 days in the treatment of acute otitis media. A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse event profile seen was comparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes. (See CLINICAL STUDIES.)

The following adverse reactions have been reported for ampicillin-class antibiotics:

Gastrointestinal

Diarrhea, nausea, vomiting, indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment. (See WARNINGS.)

Hypersensitivity Reactions

Skin rashes, pruritus, urticaria, angioedema, serum sickness−like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), erythema multiforme (rarely Stevens-Johnson syndrome), acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and an occasional case of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported. These reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise. Serious and occasional fatal hypersensitivity (anaphylactic) reactions can occur with oral penicillin. (See WARNINGS.)

Liver

A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibiotics, but the significance of these findings is unknown. Hepatic dysfunction, including hepatitis and cholestatic jaundice, (See CONTRAINDICATIONS.) increases in serum transaminases (AST and/or ALT), serum bilirubin and/or alkaline phosphatase, has been infrequently reported with AUGMENTIN. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. On rare occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications.

Renal

Interstitial nephritis and hematuria have been reported rarely. Crystalluria has also been reported (see OVERDOSAGE).

Hemic and Lymphatic Systems

Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytosis was noted in less than 1% of the patients treated with AUGMENTIN. There have been reports of increased prothrombin time in patients receiving AUGMENTIN and anticoagulant therapy concomitantly.

Central Nervous System

Agitation, anxiety, behavioral changes, confusion, convulsions, dizziness, insomnia, and reversible hyperactivity have been reported rarely.

Miscellaneous

Tooth discoloration (brown, yellow, or gray staining) has been rarely reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

Overdosage

Following overdosage, patients have experienced primarily gastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea. Rash, hyperactivity, or drowsiness have also been observed in a small number of patients.

In the case of overdosage, discontinue AUGMENTIN, treat symptomatically, and institute supportive measures as required. If the overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed. A prospective study of 51 pediatric patients at a poison center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.3

Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin.

Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.

Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of both amoxicillin and clavulanate. Both amoxicillin and clavulanate are removed from the circulation by hemodialysis.

Augmentin Chewable Dosage and Administration

Dosage

Pediatric Patients

Based on the amoxicillin component, AUGMENTIN should be dosed as follows:

Neonates and infants aged <12 weeks (3 months)

Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended dose of AUGMENTIN is 30 mg/kg/day divided q12h, based on the amoxicillin component. Clavulanate elimination is unaltered in this age group. Experience with the 200 mg/5 mL formulation in this age group is limited and, thus, use of the 125 mg/5 mL oral suspension is recommended.

Patients aged 12 weeks (3 months) and older

INFECTIONS

DOSING REGIMEN

q12h

q8h

200 mg/5 mL or 400 mg/5 mL oral suspension

125 mg/5 mL or 250 mg/5 mL oral suspension

Otitis media, sinusitis, lower respiratory tract infections, and more severe infections

45 mg/kg/day q12h

40 mg/kg/day q8h

Less severe infections

25 mg/kg/day q12h

20 mg/kg/day q8h

The q12h regimen is recommended as it is associated with significantly less diarrhea. (See CLINICAL STUDIES.) However, the q12h formulations (200 mg and 400 mg) contain aspartame and should not be used by phenylketonurics.

Each strength of suspension of AUGMENTIN is available as a chewable tablet for use by older children.

Duration of therapy studied and recommended for acute otitis media is 10 days.

Pediatric Patients Weighing 40 kg and More

Should be dosed according to the following adult recommendations: The usual adult dose is one 500-mg tablet of AUGMENTIN every 12 hours or one 250-mg tablet of AUGMENTIN every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one 875-mg tablet of AUGMENTIN every 12 hours or one 500-mg tablet of AUGMENTIN every 8 hours. Among adults treated with 875 mg every 12 hours, significantly fewer experienced severe diarrhea or withdrawals with diarrhea versus adults treated with 500 mg every 8 hours. For detailed adult dosage recommendations, please see complete prescribing information for tablets of AUGMENTIN.

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals. (See WARNINGS.)

Adults

Adults who have difficulty swallowing may be given the 125 mg/5 mL or 250 mg/5 mL suspension in place of the 500-mg tablet. The 200 mg/5 mL suspension or the 400 mg/5 mL suspension may be used in place of the 875-mg tablet. See dosage recommendations above for children weighing 40 kg or more.

The 250-mg tablet of AUGMENTIN and the 250-mg chewable tablet do not contain the same amount of clavulanic acid (as the potassium salt). The 250-mg tablet of AUGMENTIN contains 125 mg of clavulanic acid, whereas the 250-mg chewable tablet contains 62.5 mg of clavulanic acid. Therefore, the 250-mg tablet of AUGMENTIN and the 250-mg chewable tablet should not be substituted for each other, as they are not interchangeable.

Due to the different amoxicillin to clavulanic acid ratios in the 250-mg tablet of AUGMENTIN (250/125) versus the 250-mg chewable tablet of AUGMENTIN (250/62.5), the 250-mg tablet of AUGMENTIN should not be used until the child weighs at least 40 kg and more.

Directions for Mixing Oral Suspension

Prepare a suspension at time of dispensing as follows: Tap bottle until all the powder flows freely. Add approximately 2/3 of the total amount of water for reconstitution (see table below) and shake vigorously to suspend powder. Add remainder of the water and again shake vigorously.

AUGMENTIN 125 mg/5 mL Suspension

Bottle Size

Amount of Water

Required for Reconstitution

75 mL

67 mL

100 mL

90 mL

150 mL

134 mL

Each teaspoonful (5 mL) will contain 125 mg amoxicillin and 31.25 mg of clavulanic acid as the potassium salt.

AUGMENTIN 200 mg/5 mL Suspension

Bottle Size

Amount of Water

Required for Reconstitution

50 mL

50 mL

75 mL

75 mL

100 mL

95 mL

Each teaspoonful (5 mL) will contain 200 mg amoxicillin and 28.5 mg of clavulanic acid as the potassium salt.

AUGMENTIN 250 mg/5 mL Suspension

Bottle Size

Amount of Water

Required for Reconstitution

75 mL

65 mL

100 mL

87 mL

150 mL

130 mL

Each teaspoonful (5 mL) will contain 250 mg amoxicillin and 62.5 mg of clavulanic acid as the potassium salt.

AUGMENTIN 400 mg/5 mL Suspension

Bottle Size

Amount of Water

Required for Reconstitution

50 mL

50 mL

75 mL

70 mL

100 mL

90 mL

Each teaspoonful (5 mL) will contain 400 mg amoxicillin and 57.0 mg of clavulanic acid as the potassium salt.

Note: SHAKE ORAL SUSPENSION WELL BEFORE USING.

Reconstituted suspension must be stored under refrigeration and discarded after 10 days.

Administration: AUGMENTIN may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when AUGMENTIN is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, AUGMENTIN should be taken at the start of a meal.

How is Augmentin Chewable Supplied

AUGMENTIN 125 mg/5 mL for Oral Suspension: Each 5mL of reconstituted banana-flavored suspension contains 125mg amoxicillin and 31.25mg clavulanic acid as the potassium salt.

NDC 0029-6085-3975 mL bottle NDC 0029-6085-22150 mL bottle

NDC 0029-6085-23 100 mL bottle

AUGMENTIN 200 mg/5 mL for Oral Suspension: Each 5 mL of reconstituted orange-flavored suspension contains 200 mg amoxicillin and 28.5 mg clavulanic acid as the potassium salt.

NDC 0029-6087-29 50 mL bottle NDC 0029-6087-51 100 mL bottle

NDC 0029-6087-39 75 mL bottle

AUGMENTIN 250 mg/5 mL for Oral Suspension: Each 5mL of reconstituted orange-flavored suspension contains 250mg amoxicillin and 62.5mg clavulanic acid as the potassium salt.

NDC 0029-6090-39 75 mL bottle NDC 0029-6090-22 150 mL bottle

NDC 0029-6090-23 100 mL bottle

AUGMENTIN 400 mg/5 mL for Oral Suspension: Each 5mL of reconstituted orange-flavored suspension contains 400mg amoxicillin and 57mg clavulanic acid as the potassium salt.

NDC 0029-6092-29 50 mL bottle NDC 0029-6092-51 100 mL bottle

NDC 0029-6092-39 75 mL bottle

AUGMENTIN 125-mg Chewable Tablets: Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 189, contains 125mg amoxicillin as the trihydrate and 31.25mg clavulanic acid as the potassium salt.

NDC 0029-6073-47 carton of 30 tablets

AUGMENTIN 200-mg Chewable Tablets: Each mottled pink, round, biconvex, cherry-banana-flavored tablet contains 200 mg amoxicillin as the trihydrate and 28.5 mg clavulanic acid as the potassium salt.

NDC 0029-6071-12 carton of 20 tablets

AUGMENTIN 250-mg Chewable Tablets: Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 190, contains 250 mg amoxicillin as the trihydrate and 62.5 mg clavulanic acid as the potassium salt.

NDC 0029-6074-47 carton of 30 tablets

AUGMENTIN 400-mg Chewable Tablets: Each mottled pink, round, biconvex, cherry-banana-flavored tablet contains 400 mg amoxicillin as the trihydrate and 57.0 mg clavulanic acid as the potassium salt.

NDC 0029-6072-12 carton of 20 tablets

AUGMENTIN is Also Supplied as:

AUGMENTIN 250-mg Tablets (250 mg amoxicillin/125 mg clavulanic acid):

NDC 0029-6075-27 bottles of 30 NDC 0029-6075-31 100 Unit Dose tablets

AUGMENTIN 500-mg Tablets (500 mg amoxicillin/125 mg clavulanic acid):

NDC 0029-6080-12 bottles of 20 NDC 0029-6080-31 100 Unit Dose tablets

AUGMENTIN 875-mg Tablets (875mg amoxicillin/125mg clavulanic acid):

NDC 0029-6086-12 bottles of 20 NDC 0029-6086-21 100 Unit Dose tablets

Store tablets and dry powder at or below 25°C (77°F). Dispense in original containers. Store reconstituted suspension under refrigeration. Discard unused suspension after 10 days.

Clinical Studies

In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided q12h) of AUGMENTIN for 10 days versus 40/10 mg/kg/day (divided q8h) of AUGMENTIN for 10 days in the treatment of acute otitis media. Only the suspension formulations were used in this trial. A total of 575 patients were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., ≥84%) per treatment group. Strict otitis media-specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow-up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2-4 days after the completion of therapy) and at the follow-up visit (defined as 22-28 days post-completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87.2% (n = 265) and 82.3% (n = 260) for 45 mg/kg/day q12h and 40 mg/kg/day q8h, respectively. At follow-up, 67.1% (n = 249) and 68.7% (n = 243) for 45 mg/kg/day q12h and 40 mg/kg/day q8h, respectively.

The incidence of diarrhea††† was significantly lower in patients in the q12h treatment group compared to patients who received the q8h regimen (14.3% and 34.3%, respectively). In addition, the number of patients with either severe diarrhea or who were withdrawn with diarrhea was significantly lower in the q12h treatment group (3.1% and 7.6% for the q12h/10 day and q8h/10 day, respectively). In the q12h treatment group, 3 patients (1.0%) were withdrawn with an allergic reaction, while 1 patient (0.3%) in the q8h group was withdrawn for this reason. The number of patients with a candidal infection of the diaper area was 3.8% and 6.2% for the q12h and q8h groups, respectively.

It is not known if the finding of a statistically significant reduction in diarrhea with the oral suspensions dosed q12h, versus suspensions dosed q8h, can be extrapolated to the chewable tablets. The presence of mannitol in the chewable tablets may contribute to a different diarrhea profile. The q12h oral suspensions are sweetened with aspartame only.

††† Diarrhea was defined as either: (a) 3 or more watery or 4 or more loose/watery stools in 1 day; OR (b) 2 watery stools per day or 3 loose/watery stools per day for 2 consecutive days.

REFERENCES

  1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically − Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25. NCCLS, Villanova, PA, Dec. 1993.
  2. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Disk Susceptibility Tests − Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24. NCCLS, Villanova, PA, Dec. 1993.
  3. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol 1988;30:66-67.

AUGMENTIN is a registered trademark of GlaxoSmithKline.

CLINITEST is a registered trademark of Miles, Inc.

CLINISTIX is a registered trademark of Bayer Corporation.

GlaxoSmithKline

Research Triangle Park, NC 27709

©2006, GlaxoSmithKline All rights reserved.

December 2006 AG:PL17
AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6085 Dosage Form POWDER, FOR SUSPENSION
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 125 MILLIGRAM  In 5 MILLILITER
clavulanate potassium (clavulanic acid) Active 31.25 MILLIGRAM  In 5 MILLILITER
colloidal silicon dioxide Inactive  
flavorings Inactive  
xanthan gum Inactive  
aspartame Inactive  
hypromellose Inactive  
mannitol Inactive  
silica gel Inactive  
silicon dioxide Inactive  
sodium saccharin Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6085-39 75 MILLILITER In 1 BOTTLE None
2 0029-6085-23 100 MILLILITER In 1 BOTTLE None
3 0029-6085-22 150 MILLILITER In 1 BOTTLE None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6087 Dosage Form POWDER, FOR SUSPENSION
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 200 MILLIGRAM  In 5 MILLILITER
clavulanate potassium (clavulanic acid) Active 28.5 MILLIGRAM  In 5 MILLILITER
colloidal silicon dioxide Inactive  
flavorings Inactive  
xanthan gum Inactive  
aspartame Inactive  
hypromellose Inactive  
mannitol Inactive  
silica gel Inactive  
silicon dioxide Inactive  
sodium saccharin Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6087-29 50 MILLILITER In 1 BOTTLE None
2 0029-6087-39 75 MILLILITER In 1 BOTTLE None
3 0029-6087-51 100 MILLILITER In 1 BOTTLE None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6090 Dosage Form POWDER, FOR SUSPENSION
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 250 MILLIGRAM  In 5 MILLILITER
clavulanate potassium (clavulanic acid) Active 62.5 MILLIGRAM  In 5 MILLILITER
colloidal silicon dioxide Inactive  
flavorings Inactive  
xanthan gum Inactive  
aspartame Inactive  
hypromellose Inactive  
mannitol Inactive  
silica gel Inactive  
silicon dioxide Inactive  
sodium saccharin Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6090-39 75 MILLILITER In 1 BOTTLE None
2 0029-6090-23 100 MILLILITER In 1 BOTTLE None
3 0029-6090-22 150 MILLILITER In 1 BOTTLE None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6092 Dosage Form POWDER, FOR SUSPENSION
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 400 MILLIGRAM  In 5 MILLILITER
clavulanate potassium (clavulanic acid) Active 57 MILLIGRAM  In 5 MILLILITER
colloidal silicon dioxide Inactive  
flavorings Inactive  
xanthan gum Inactive  
aspartame Inactive  
hypromellose Inactive  
mannitol Inactive  
silica gel Inactive  
silicon dioxide Inactive  
sodium saccharin Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6092-29 50 MILLILITER In 1 BOTTLE None
2 0029-6092-39 75 MILLILITER In 1 BOTTLE None
3 0029-6092-51 100 MILLILITER In 1 BOTTLE None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6073 Dosage Form TABLET, CHEWABLE
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 125 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 31.25 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
flavorings Inactive  
aspartame Inactive  
mannitol Inactive  
sodium saccharin Inactive  
magnesium stearate Inactive  
D&C Yellow No. 10 Inactive  
FD&C Red No. 40 Inactive  
glycine Inactive  
succinic acid Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color YELLOW (mottled yellow) Score 1
Shape ROUND Symbol false
Imprint Code BMP;189 Coating false
Size 11mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6073-47 30 TABLET In 1 CARTON None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6071 Dosage Form TABLET, CHEWABLE
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 200 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 28.5 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
flavorings Inactive  
aspartame Inactive  
mannitol Inactive  
sodium saccharin Inactive  
magnesium stearate Inactive  
D&C Yellow No. 10 Inactive  
FD&C Red No. 40 Inactive  
glycine Inactive  
succinic acid Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color PINK (mottled pink) Score 1
Shape ROUND Symbol false
Imprint Code Coating false
Size 11mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6071-12 20 TABLET In 1 CARTON None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6074 Dosage Form TABLET, CHEWABLE
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 250 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 62.5 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
flavorings Inactive  
aspartame Inactive  
mannitol Inactive  
sodium saccharin Inactive  
magnesium stearate Inactive  
D&C Yellow No. 10 Inactive  
FD&C Red No. 40 Inactive  
glycine Inactive  
succinic acid Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color YELLOW (mottled yellow) Score 1
Shape ROUND Symbol false
Imprint Code BMP;190 Coating false
Size 14mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6074-47 30 TABLET In 1 CARTON None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6072 Dosage Form TABLET, CHEWABLE
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 400 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 57.0 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
flavorings Inactive  
aspartame Inactive  
mannitol Inactive  
sodium saccharin Inactive  
magnesium stearate Inactive  
D&C Yellow No. 10 Inactive  
FD&C Red No. 40 Inactive  
glycine Inactive  
succinic acid Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color PINK (mottled pink) Score 1
Shape ROUND Symbol false
Imprint Code Coating false
Size 14mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6072-12 20 TABLET In 1 CARTON None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6075 Dosage Form TABLET, FILM COATED
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 250 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 125 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
magnesium stearate Inactive  
hypromellose Inactive  
microcrystalline cellulose Inactive  
polyethylene glycol Inactive  
sodium starch glycolate Inactive  
titanium dioxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE Score 1
Shape OVAL Symbol false
Imprint Code AUGMENTIN;250/125 Coating true
Size 18mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6075-27 30 TABLET In 1 BOTTLE None
2 0029-6075-31 100 TABLET In 1 BOX, UNIT-DOSE None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6080 Dosage Form TABLET, FILM COATED
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 500 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 125 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
magnesium stearate Inactive  
hypromellose Inactive  
microcrystalline cellulose Inactive  
polyethylene glycol Inactive  
sodium starch glycolate Inactive  
titanium dioxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE Score 1
Shape OVAL Symbol false
Imprint Code AUGMENTIN;500/125 Coating true
Size 20mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6080-12 20 TABLET In 1 BOTTLE None
2 0029-6080-31 100 TABLET In 1 BOX, UNIT-DOSE None

AUGMENTIN (amoxicillin and clavulanate potassium)
PRODUCT INFO
Product Code 0029-6086 Dosage Form TABLET, FILM COATED
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
amoxicillin (amoxicillin) Active 875 MILLIGRAM  In 1 TABLET
clavulanate potassium (clavulanic acid) Active 125 MILLIGRAM  In 1 TABLET
colloidal silicon dioxide Inactive  
magnesium stearate Inactive  
hypromellose Inactive  
microcrystalline cellulose Inactive  
polyethylene glycol Inactive  
sodium starch glycolate Inactive  
titanium dioxide Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE Score 2
Shape OVAL Symbol false
Imprint Code AUGMENTIN;875 Coating true
Size 22mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0029-6086-12 20 TABLET In 1 BOTTLE None
2 0029-6086-21 100 TABLET In 1 BOX, UNIT-DOSE None

Revised: 01/2007


Professional Monographs (FDA)

Online Pharmacies

Online Pharmacies
Online Generic Pharmacy
ED Pills Online Pharmacy

Medical News

White House calls for task force to tackle antibiotic-resistant bugs

By P.J. Huffstutter (Reuters) - The U.S. government will set up a task force and presidential advisory council to tackle the growing threat of antibiotic resistance, setting a Feb. 15 deadline for it to outline specific steps, White House advisers said on Thursday. The secretaries of Defense, Agriculture and Health and Human Services will set up the task force to advise on steps to ensure the remaining medically important antibiotics available to treat humans stay effective and look at their use in animal feed. ..... more >>
Thu, 18 Sep 2014

FDA approves Eli Lilly's injectable diabetes drug

WASHINGTON (AP) — The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly and Co. for adults with the most common form of the disease... more >>
Thu, 18 Sep 2014

Ailing Rob Ford urges voters to back brother for Toronto mayor

TORONTO (Reuters) - Toronto Mayor Rob Ford, in his first public remarks since doctors revealed he has cancer, has asked residents of Canada's largest city to vote for his brother Doug, who has replaced him on the ballot in next month's mayoral election. "I'm encouraging my brother to jump into this race wholeheartedly right now," he said in a three-minute audio recording released on Thursday. "Toronto needs Doug Ford as mayor. ..... more >>
Thu, 18 Sep 2014

Vivus' Stendra gets FDA approval for use 15 minutes before sex

(Reuters) - The erectile dysfunction drug Stendra, currently approved by the U.S. Food and Drug Administration for use 30 minutes before sex, has now been approved for use as little as 15 minutes before sex, the drug's developers said on Thursday. Stendra is the first FDA-approved erectile dysfunction drug that can be taken 15 minutes prior to sexual activity. The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc. Pfizer Inc's blockbuster erectile dysfunction drug, Viagra, can be taken about an hour before sex. ..... more >>
Thu, 18 Sep 2014

Bayer hits record high on move to list plastics business

By Ludwig Burger and Georgina Prodhan FRANKFURT (Reuters) - Germany's Bayer plans to list its plastics business on the stock market in a deal that could value the division at about 10 billion euros ($13 billion) and allow the group to focus on its more profitable life-science businesses. News of a spin-off that Chief Executive Marijn Dekkers said will free up money for investment in Bayer's healthcare, veterinary drugs and crop protection businesses, lifted the company's shares to a record high. By 1535 GMT (11.35 a.m. EDT) the shares had gained 6.2 percent to 112.70 euros, outperforming a 0. ..... more >>
Thu, 18 Sep 2014

Secure Italian military lab to grow medical marijuana

By Steve Scherer ROME (Reuters) - Italy said on Thursday it would grow medical marijuana at a secure military lab outside Florence and distribute it through pharmacies to slash costs and make it more easily available to the sick. The use of medical marijuana or cannabis derivatives to treat patients has been legal in Italy since 2007, but only a few dozen people took it through the national healthcare system in 2013 because of its prohibitive cost. ..... more >>
Thu, 18 Sep 2014

Former addicts may be at lower risk of new addictions

By Kathryn Doyle NEW YORK (Reuters Health) - People who manage to get clean after being addicted to drugs are at lower risk of becoming addicted to something else in the future than people who never overcame the first substance use disorder, according to a new study.“The results are surprising, they cut against conventional clinical lore which holds that people who stop one addiction are at increased risk of picking up a new one,” said senior author Dr. Mark Olfson, a professor of clinical psychiatry at Columbia University Medical Center in New York. ..... more >>
Thu, 18 Sep 2014

Merck KGaA seeks partner for immuno-oncology drug by year-end

FRANKFURT (Reuters) - German drugs and chemicals maker Merck KGaA is in advanced talks with potential partners interested in its experimental cancer immunotherapy drug and expects to clinch a partnership deal before the end of the year. Its medicine is a so-called anti-PD-L1 agent, one of a number of new drugs from rival companies within the hot research area of immuno-oncology that are designed to make tumor cells more vulnerable to attack by the body’s immune system. U.S. ..... more >>
Thu, 18 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment: study

By Shida Chayesteh COPENHAGEN (Reuters) - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study. Ryzodeg combines Tresiba, Novo Nordisk's great hope for future growth, with insulin aspart, a man-made form of insulin, also known as NovoRapid, in a single pen injector. Novo Nordisk, the world's biggest insulin maker, has launched Ryzodeg commercially in Mexico. ..... more >>
Thu, 18 Sep 2014

Merck KGaA appoints pharma head Oschmann as deputy CEO

FRANKFURT (Reuters) - German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday. Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said. The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016. Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. ..... more >>
Thu, 18 Sep 2014

First French Ebola patient 'still in Liberia waiting for airlift'

Paris (AFP) - The first French person to have been infected by the deadly Ebola virus was still in Liberia Thursday and was waiting to be airlifted home, according to the humanitarian group she works for... more >>
Wed, 17 Sep 2014

GSK melanoma pill backed by UK cost watchdog with price cut

LONDON (Reuters) - Britain's healthcare cost agency NICE has recommended a third new drug for melanoma, this time from GlaxoSmithKline, after the drugmaker offered to supply it at a discount to the state-run National Health Service. GSK currently markets Tafinlar but the product will soon transfer to Novartis under a deal between the two companies to trade assets. Tafinlar is an oral medicine that works in a similar way to Roche's already recommended drug Zelboraf. Both target a specific gene mutation linked to around half of aggressive melanomas. ..... more >>
Wed, 17 Sep 2014

FDA panel backs limiting use of testosterone replacement drugs

By Toni Clarke (Reuters) - Testosterone replacement therapies should be reserved for men with specific medical conditions that impair function of the testicles, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. The panel also recommended that companies be required to conduct additional studies to assess the cardiovascular risk of their products for patients with age-related low testosterone. ..... more >>
Wed, 17 Sep 2014

Humana CEO: New competition curbs Obamacare plan prices

By Caroline Humer BOSTON (Reuters) - New competition between health insurers offering so-called Obamacare plans in 2015 is having an impact on the pricing of such coverage, based on a first look at proposed insurance premiums, the head of Humana Inc said on Wednesday. The state insurance exchanges offering coverage under the Affordable Care Act. President Barack Obama's landmark healthcare law will begin enrolling customers for 2015 benefits in mid-November. ..... more >>
Wed, 17 Sep 2014
Consumer Information MedFacts, Cerner Multum, Micromedex, PDR and Professional Monographs (FDA)

augmentin.org © 2007-2011 Augmentin  Augmentin Chewable FDA